Long-term Immunogenicity of a HPV Vaccine in SLE
NCT02477254 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 84
Last updated 2016-10-19
Summary
To study the 5-year immunogenicity against a quadrivalent HPV vaccine in patients with SLE and healthy controls.
Conditions
Interventions
- BIOLOGICAL
-
Vaccination
A quadrivalent HPV vaccine
Sponsors & Collaborators
-
Tuen Mun Hospital
lead OTHER_GOV
Principal Investigators
-
CC Mok, MD · Tuen Mun Hospital
Eligibility
- Min Age
- 18 Years
- Max Age
- 35 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-07-31
- Primary Completion
- 2016-05-31
- Completion
- 2016-10-31
Countries
- China
Study Locations
More Related Trials
-
Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.
NCT06150651 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus
NCT06137053 ·Status: RECRUITING
-
An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)
NCT01018238 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus
NCT00657189 ·Status: COMPLETED ·Phase: PHASE2
-
BLYS and IFN in SLE
NCT00611611 ·Status: COMPLETED
-
Recombinant Zoster Vaccine in Stable SLE Patients
NCT04516408 ·Status: UNKNOWN ·Phase: NA
-
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
NCT06585514 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
NCT04082416 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus
NCT00611663 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
NCT06535412 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus
NCT05247203 ·Status: COMPLETED ·Phase: PHASE1
-
Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
NCT03371251 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Immunogenicity, Reactogenicity of Shingrix in SLE
NCT06001606 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
NCT06161116 ·Status: TERMINATED ·Phase: PHASE2
-
The Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HC022 Injection in Subjects With SLE/CLE
NCT07306585 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
NCT06791772 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
NCT00556192 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus
NCT00482989 ·Status: COMPLETED ·Phase: PHASE1
-
Long-Term Outcomes in SLE at Peking University People's Hospital
NCT07005479 ·Status: RECRUITING
-
Safety of the Herpes Zoster Subunit Vaccine in Lupus
NCT05559671 ·Status: RECRUITING ·Phase: PHASE4
-
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
NCT02885610 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus
NCT06106893 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
NCT04895241 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia
NCT01345253 ·Status: COMPLETED ·Phase: PHASE3